Literature DB >> 2350530

The effect of food and bile acid administration on the relative bioavailability of cyclosporin.

A Lindholm1, S Henricsson, R Dahlqvist.   

Abstract

1. The relative bioavailability of cyclosporin was studied in 11 healthy volunteers after single oral capsule doses of cyclosporin on three separate occasions; fasting, with breakfast and with breakfast together with bile acid tablets (400 mg of cholic acid and 100 mg of dehydrocholic acid). 2. There was a significant increase in the area under the blood concentration vs time curve (AUC) of cyclosporin when the drug was taken together with breakfast and bile acid tablets (9078 ng ml-1 h) as compared with breakfast alone (7453 ng ml-1 h, P less than 0.05) or fasting conditions (7283 ng ml-1 h, P less than 0.01). 3. A blood drug concentration vs time curve displaying two peaks was present in 9/11 subjects when cyclosporin was taken with breakfast or with breakfast and bile acid tablets, but only one peak was present when cyclosporin was taken during fasting, suggesting an enterohepatic circulation of cyclosporin or a second absorption phase after the meal. 4. In a separate study, 12 h trough blood cyclosporin concentrations were measured before and after 1 week of bile acid treatment in 19 clinically stable, out-patient transplant recipients who were treated with oral cyclosporin solution (mean dose 2.0 mg kg-1 twice daily). The administration of cyclosporin was not standardized with regard to food intake. There was no significant difference in the blood concentrations of cyclosporin before and after bile acid treatment (114 +/- 38 ng ml-1 vs 121 +/- 38 ng ml-1).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2350530      PMCID: PMC1380153          DOI: 10.1111/j.1365-2125.1990.tb03677.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  22 in total

1.  Monoclonal antibodies to ciclosporin.

Authors:  V Quesniaux; R Tees; M H Schreier; R M Wenger; P Donatsch; M H Van Regenmortel
Journal:  Prog Allergy       Date:  1986

2.  The effect of food and cholestyramine on the absorption of cyclosporine in cardiac transplant recipients.

Authors:  A Keogh; R Day; L Critchley; G Duggin; D Baron
Journal:  Transplant Proc       Date:  1988-02       Impact factor: 1.066

3.  Pharmacokinetics of oral cyclosporin A (Sandimmun) in healthy subjects.

Authors:  J Grevel; E Nüesch; E Abisch; K Kutz
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

4.  Cyclosporine blood concentrations in the management of renal transplant recipients.

Authors:  M E Rogerson; J T Marsden; K E Reid; M Bewick; D W Holt
Journal:  Transplantation       Date:  1986-02       Impact factor: 4.939

5.  Potential of monoclonal antibodies to improve therapeutic monitoring of cyclosporine.

Authors:  V Quesniaux; R Tees; M H Schreier; G Maurer; M H van Regenmortel
Journal:  Clin Chem       Date:  1987-01       Impact factor: 8.327

6.  On the dose dependency of cyclosporin A absorption and disposition in healthy volunteers.

Authors:  J P Reymond; J L Steimer; W Niederberger
Journal:  J Pharmacokinet Biopharm       Date:  1988-08

7.  Absorption profiles of renal allograft recipients receiving oral doses of cyclosporine: a pharmacokinetic study.

Authors:  T M Phillips; S A Karmi; S C Frantz; H F Henriques
Journal:  Transplant Proc       Date:  1988-04       Impact factor: 1.066

8.  Quantitative determination of cyclosporin A in whole blood and plasma by high performance liquid chromatography.

Authors:  N Shibata; T Minouchi; Y Hayashi; T Ono; H Shimakawa
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1987-08

9.  Effect of bile on cyclosporin absorption in liver transplant patients.

Authors:  M U Mehta; R Venkataramanan; G J Burckart; R J Ptachcinski; B Delamos; S Stachak; D H Van Thiel; S Iwatsuki; T E Starzl
Journal:  Br J Clin Pharmacol       Date:  1988-05       Impact factor: 4.335

10.  Trough levels and concentration time curves of cyclosporine in patients undergoing renal transplantation.

Authors:  F J Frey; F F Horber; B M Frey
Journal:  Clin Pharmacol Ther       Date:  1988-01       Impact factor: 6.875

View more
  21 in total

1.  Time effects of food intake on the pharmacokinetics and pharmacodynamics of quazepam.

Authors:  Norio Yasui-Furukori; Takenori Takahata; Tsuyoshi Kondo; Kazuo Mihara; Sunao Kaneko; Tomonori Tateishi
Journal:  Br J Clin Pharmacol       Date:  2003-04       Impact factor: 4.335

2.  Combination therapy with diltiazem plus CsA/MMF/Pred or CsA/Aza/Pred triple immunosuppressive regimens for use in clinical kidney transplantation in Northwestern China.

Authors:  Yong Song; Wujun Xue; Puxun Tian; Xiaoming Ding; Xiaoming Pan; Hang Yan; Jun Hou; Xinshun Feng; Heli Xiang; Xiaohui Tian; Gaoping Qin; Xiaohu Fan
Journal:  Eur J Clin Pharmacol       Date:  2011-01-29       Impact factor: 2.953

3.  Predicting pharmacokinetic food effects using biorelevant solubility media and physiologically based modelling.

Authors:  Hannah M Jones; Neil Parrott; Gerd Ohlenbusch; Thierry Lavé
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

4.  A phase I study to assess the effect of food on the single dose bioavailability of the THC/CBD oromucosal spray.

Authors:  C G Stott; L White; S Wright; D Wilbraham; G W Guy
Journal:  Eur J Clin Pharmacol       Date:  2012-10-04       Impact factor: 2.953

Review 5.  A Review of Food-Drug Interactions on Oral Drug Absorption.

Authors:  Jianyuan Deng; Xiao Zhu; Zongmeng Chen; Chun Ho Fan; Him Shek Kwan; Chi Ho Wong; Ka Yi Shek; Zhong Zuo; Tai Ning Lam
Journal:  Drugs       Date:  2017-11       Impact factor: 9.546

6.  Diltiazem augments the influence of MDR1 genotype status on cyclosporine concentration in Chinese patients with renal transplantation.

Authors:  Yi-xi Wang; Jia-li Li; Xue-ding Wang; Yu Zhang; Chang-xi Wang; Min Huang
Journal:  Acta Pharmacol Sin       Date:  2015-04-20       Impact factor: 6.150

7.  Influence of a fat-rich meal on the pharmacokinetics of a new oral formulation of cyclosporine in a crossover comparison with the market formulation.

Authors:  E A Mueller; J M Kovarik; J B van Bree; J Grevel; P W Lücker; K Kutz
Journal:  Pharm Res       Date:  1994-01       Impact factor: 4.200

Review 8.  Novel oral drug formulations. Their potential in modulating adverse effects.

Authors:  A T Florence; P U Jani
Journal:  Drug Saf       Date:  1994-03       Impact factor: 5.606

9.  Diltiazem co treatment with cyclosporine for induction of disease remission in sight-threatening non-infectious intraocular inflammation.

Authors:  Usama Shalaby
Journal:  Jpn J Ophthalmol       Date:  2016-12-10       Impact factor: 2.447

10.  Pharmacokinetics, tissue distribution and mass balance of radiolabeled dihydroartemisinin in male rats.

Authors:  Lisa H Xie; Qigui Li; Jing Zhang; Peter J Weina
Journal:  Malar J       Date:  2009-05-26       Impact factor: 2.979

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.